BioMed Valley's ulixertinib leads to partial responses in Phase I for solid tumors

BioMed Valley Discoveries Inc. (Kansas City, Mo.) said twice-daily oral ulixertinib (BVD-523) at doses of ≥600 mg led to 14 partial responses in about 101 evaluable patients with advanced solid tumors in a two-part Phase I trial. Data were published in Cancer Discovery.

The open-label, U.S. trial’s dose-escalation first part enrolled 27 patients to receive twice-daily 10-900 mg doses of ulixertinib. The company determined twice-daily 600 mg ulixertinib to be the maximum tolerated dose (MTD) and recommended Phase II dose. The trial’s dose-expansion second part enrolled 108 patients to receive twice-daily 600 mg ulixertinib...